NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ALMS

Alumis Inc

Jul 01 • 04:00PM ET

3.02

Dollar change +0.02
Percentage change 0.67	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN GILD REGN VRTX BIIB MRNA INCY BMY ABBV PFE

| Held by: VTI IWM VXF IBB IWN VTWO SCHA IWC VHT PRFZ

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-6.32	Insider Own	34.47%	Shs Outstand	103.19M	Perf Week	0.33%
Market Cap	311.63M	Forward P/E	-	EPS next Y	-3.02	Insider Trans	1.39%	Shs Float	67.62M	Perf Month	-13.71%
Enterprise Value	134.76M	PEG	-	EPS next Q	-1.30	Inst Own	23.29%	Short Float	4.76%	Perf Quarter	-50.81%
Income	-343.35M	P/S	17.92	EPS this Y	59.17%	Inst Trans	76.30%	Short Ratio	3.81	Perf Half Y	-64.09%
Sales	17.39M	P/B	0.98	EPS next Y	28.82%	ROA	-156.54%	Short Interest	3.22M	Perf YTD	-61.58%
Book/sh	3.09	P/C	1.49	EPS next 5Y	36.78%	ROE	-247.05%	52W High	13.50 -77.63%	Perf Year	-
Cash/sh	2.02	P/FCF	-	EPS past 3/5Y	-58.27% -	ROIC	-173.72%	52W Low	2.76 9.42%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	81.38%	Volatility	10.42% 9.13%	Perf 5Y	-
Dividend TTM	-	EV/Sales	7.75	EPS Y/Y TTM	-93.94%	Oper. Margin	-1995.45%	ATR (14)	0.38	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.73	Sales Y/Y TTM	-	Profit Margin	-1974.51%	RSI (14)	40.31	Recom	1.17
Dividend Gr. 3/5Y	- -	Current Ratio	3.73	EPS Q/Q	-89.62%	SMA20	-4.57%	Beta	-1.87	Target Price	19.40
Payout	-	Debt/Eq	0.19	Sales Q/Q	-	SMA50	-24.79%	Rel Volume	0.94	Prev Close	3.00
Employees	168	LT Debt/Eq	0.17	Earnings	May 14 AMC	SMA200	-57.87%	Avg Volume	845.31K	Price	3.02
IPO	Jun 28, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	-22.48% 943.32%	Trades		Volume	800,598	Change	0.67%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-10-25	Resumed	Guggenheim	Buy	$18
Jan-30-25	Initiated	Oppenheimer	Outperform	$32
Oct-31-24	Initiated	Robert W. Baird	Outperform	$25
Oct-17-24	Initiated	H.C. Wainwright	Buy	$30
Jul-23-24	Initiated	Morgan Stanley	Overweight	$36
Jul-23-24	Initiated	Leerink Partners	Outperform	$29
Jul-23-24	Initiated	Guggenheim	Buy	$32
Jul-23-24	Initiated	Cantor Fitzgerald	Overweight

May-30-25 05:23AM	Alumis concludes enrolment in Phase III programme of plaque psoriasis therapy (Clinical Trials Arena) -10.49%
May-29-25 04:15PM	Alumis to Present at the Jefferies Global Healthcare Investor Conference (GlobeNewswire)
07:55AM	Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis (GlobeNewswire)
May-21-25 09:10AM	Alumis Completes Merger with ACELYRIN (GlobeNewswire)
May-14-25 04:05PM	Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements (GlobeNewswire) +18.63%
01:00PM	Loading…
May-13-25 01:00PM	Alumis Stockholders Approve Merger with ACELYRIN (GlobeNewswire) -15.05%
01:00PM	ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases (GlobeNewswire)
May-06-25 04:30PM	Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote FOR the Proposed Transaction with Alumis (GlobeNewswire) +10.11%
May-02-25 01:45PM	Acelyrin urges stockholders to vote for proposed merger with Alumis (TipRanks) +19.84%
May-01-25 01:30PM	ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis (GlobeNewswire) -7.49%
Apr-29-25 01:22PM	Acelyrin should liquidate instead of merging with Alumis, investor says (BioPharma Dive) +5.10%
Apr-21-25 06:30AM	Alumis and ACELYRIN Announce Amended Merger Agreement (GlobeNewswire) -6.00%
Apr-10-25 07:00AM	3 Biopharmaceutical Stocks Bucking the Sell-Off (MarketBeat) -15.05%
Apr-07-25 01:43PM	Alumis: Biotech's Stock Gains >100% In A Month - But Risk Of Failure Is High (Seeking Alpha)
Apr-04-25 04:34PM	Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger (GlobeNewswire) +17.68%
10:51AM	Loading…
Mar-25-25 10:51AM	Alumis and Kaken sign agreement in Japan to develop ESK-001 (Pharmaceutical Technology) +5.96%
02:30AM	Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan (GlobeNewswire)
Mar-21-25 07:08AM	Why Alumis Inc. (ALMS) Went Down On Thursday? (InsiderMonkey) +5.04%
Mar-19-25 04:05PM	Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements (GlobeNewswire) -18.31%
Mar-10-25 08:00AM	Alumis to Present at Leerink's 2025 Global Healthcare Conference (GlobeNewswire)
Mar-08-25 09:00AM	Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis (GlobeNewswire)
Mar-04-25 09:01AM	Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger (GlobeNewswire)
09:01AM	ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger (GlobeNewswire)
09:00AM	ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger (GlobeNewswire)
Feb-28-25 09:08AM	Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout (GlobeNewswire)
Feb-27-25 04:15PM	Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases (GlobeNewswire)
Feb-20-25 09:00PM	ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences (GlobeNewswire)
Feb-10-25 04:45PM	Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire) -14.99%
Feb-07-25 10:44AM	Alumis and Acelyrin sign merger agreement (Pharmaceutical Technology) -13.96%
03:00AM	Immune drugmakers Alumis and Acelyrin to merge (BioPharma Dive)
04:15PM	Loading…
Feb-06-25 04:15PM	Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases (GlobeNewswire) -7.57%
Jan-30-25 02:48PM	Why Alumis (ALMS) Stock Is Advancing Today (Insider Monkey)
Jan-28-25 08:00AM	Alumis Strengthens Leadership Team with Key Appointments (GlobeNewswire)
Dec-19-24 08:00AM	Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005 (GlobeNewswire)
Nov-14-24 04:05PM	Alumis Presents Data Highlighting ESK-001's Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024 (GlobeNewswire) -12.95% -5.95%
Nov-13-24 04:05PM	Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements (GlobeNewswire)
Nov-04-24 08:00AM	Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference (GlobeNewswire)
Sep-27-24 09:00AM	Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study (GlobeNewswire) -6.77%
Sep-03-24 04:29PM	Alumis to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-13-24 04:05PM	Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements (GlobeNewswire)
Jul-29-24 08:00AM	Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis (GlobeNewswire)
Jun-27-24 11:57PM	Alumis Announces Pricing of Initial Public Offering (GlobeNewswire)

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Tananbaum James B.	Director	May 02 '25	Buy	4.62	25,000	115,500	4,227,670	May 06 09:48 PM
Tananbaum James B.	Director	May 06 '25	Buy	4.34	20,000	86,800	4,247,670	May 06 09:48 PM
Foresite Labs, LLC	10% Owner	May 02 '25	Buy	4.62	25,000	115,500	4,227,670	May 06 09:48 PM
Foresite Labs, LLC	10% Owner	May 06 '25	Buy	4.34	20,000	86,800	4,247,670	May 06 09:48 PM
Foresite Capital Management VI	10% Owner	May 02 '25	Buy	4.62	25,000	115,500	4,227,670	May 06 09:47 PM
Foresite Capital Management VI	10% Owner	May 06 '25	Buy	4.34	20,000	86,800	4,247,670	May 06 09:47 PM
AKKARAJU SRINIVAS	Director	May 05 '25	Buy	4.67	160,370	749,676	3,586,788	May 06 06:52 PM
AKKARAJU SRINIVAS	Director	May 02 '25	Buy	4.55	159,920	727,636	3,426,418	May 06 06:52 PM
Colowick Alan	Director	Apr 01 '25	Buy	6.97	16,104	112,309	16,104	Apr 03 06:05 PM
Colowick Alan	Director	Apr 02 '25	Buy	7.49	2,300	17,235	18,404	Apr 03 06:05 PM
Babler Martin	President, CEO and Chairman	Apr 01 '25	Buy	6.44	15,650	100,733	106,454	Apr 03 06:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALMS

Alumis Inc

Upgrade your FINVIZ experience